[HTML][HTML] Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the …

M Farnier, P Jones, R Severance, M Averna… - Atherosclerosis, 2016 - Elsevier
Objective To compare lipid-lowering efficacy of adding alirocumab to rosuvastatin versus
other treatment strategies (NCT01730053). Methods Patients receiving baseline
rosuvastatin regimens (10 or 20 mg) were randomized to: add-on alirocumab 75 mg every-2-
weeks (Q2W)(1-mL subcutaneous injection via pre-filled pen); add-on ezetimibe 10 mg/day;
or double-dose rosuvastatin. Patients had cardiovascular disease (CVD) and low-density
lipoprotein cholesterol (LDL–C)≥ 70 mg/dL (1.8 mmol/L) or CVD risk factors and LDL–C≥ …